Methods. Control pellets or pellets containing 80 ng bFGF were surgically implanted into wildtype C57BL/6 and VEGF-LacZ mouse corneas. The corneas were photographed, harvested, and the percentage of corneal NV was calculated. The harvested corneas were evaluated for VEGF expression. VEGF-LacZ mice received tail vein injections of an endothelial-specific lectin after pellet implantation to determine the temporal and spatial relationship between VEGF expression and corneal NV. Intraperitoneal injections of VEGF (Eur J Ophthalmol 2010, 20: 48-54) 
1 ) 48-54 20 IntrOductIOn corneal avascularity requires a balance between several endogenous angiogenic (including VEGF, bFGF) and anti-angiogenic (endostatin, thrombospondin-1) factors (1) (2) (3) (4) . VEGF trap r1r2 , a VEGF antagonist, is a soluble fusion protein combining the truncated form of the FMSlike tyrosine kinase (Flt), kinase insert domain-containing receptor (Kdr), and Fc portion of human IgG. VEGF trap r1r2 is designed to sequester and antagonize the VEGF and to prevent blood vessel formation (5, 6). Angiogenesis is involved in both normal physiologic processes as well as in pathologic conditions; such processes and conditions include embryonic vessel formation, wound healing, tumor vascularization, rheumatoid arthritis, corneal neovascularization (nV), and diabetic retinopathy (1, (7) (8) (9) (10) (11) (12) be stored at -20 ºc for several days without loss of bioactivity. corneal micropocket assays were performed as described by Kenyon et al (19) . Eight-week-old mice were anesthetized by a combined ketamine and xylazine injection. Proparacaine eyedrops were used for local anesthesia. Eye globes were proptosed with a jewelerís forceps. using an operating microscope (JKH operating surgical microscope), corneas were marked with a 3-mm trephine. corneal lamellar micropocket incisions were created parallel to the corneal plane using a modified von Graefe knife along the trephine mark. A 0.5-mm incision perpendicular to the mouse corneal surface traversing the epithelium and anterior stroma toward the center of the cornea was performed with a 1/2-inch, 30-gauge needle (Becton dickinson, Franklin Lakes, nJ, uSA). A uniformly sized Hydron pellet (0.4 x 0.4 x 0.2 mm) containing 80 ng of human bFGF (r&d Systems, Minneapolis, Mn, uSA) and 40 μg of sucrose aluminum sulfate was placed on the corneal surface at the base of the pocket with jeweler's forceps and using one arm of the forceps, the pellet was advanced to the end of the pocket. In all animals, we aimed for a 1 mm distance from the pellet to the limbus. Antibiotic ointment (bacitracin) was then applied to the operated eye to prevent infection and to decrease surface irregularities. corneal images were obtained perpendicular to the cornea at the pellet position to minimize the parallax as described previously by Kure et al (20) . two images of every pellet were obtained. the distances from limbus to pellets were measured by 3 independent observes, and were normalized to the overall average distance (4.0 mm). corneas were routinely examined and photographed. Photographs were digitized, and images were analyzed with the nIH ImageJ program.
Confocal microscopy c57BL/6 mouse eyes were obtained on days 0, 1, 4, 7, 10, 14, and 21 after bFGF and blank pellet implantation, and were frozen in Oct compound (Baxter Scientific, columbia, Md, uSA) . cryostat sections, 8 μm thick, were fixed in acetone for 10 minutes. After blocking with 1% bovine serum albumin (BSA) (Sigma-Aldrich), sections were incubated for 1 hour with rat anti-cd31 antibody (Pharmingen, San diego, cA, uSA) and goat anti-mouse VEGF antibody (r&d Systems) used at a 1:100 dilution. Secondary antibodies used were a cy5-conjugated donkey anti-rat IgG antibody and a rhodamine-conjugated donkey anti-goat basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) (13-16). Investigation of the relationship between bFGF and VEGF during angiogenesis and tumor progression has elucidated a synergistic effect between these 2 factors in the induction of angiogenesis in vitro (17). Additionally, Seghezzi et al demonstrated that bFGF induces VEGF expression in vascular endothelial cells through autocrine and paracrine mechanisms (18). In this report, we determine whether corneal keratocytes express VEGF after bFGF stimulation and whether bFGFinduced corneal nV is blocked by intraperitoneal VEGF trap r1r2 administration.
MAtErIALS And MEtHOdS

Animals
All animal studies were conducted in accordance with the Animal care and use committee Guidelines of the Massachusetts Eye and Ear Infirmary and the Association for research in Vision and Ophthalmology statement for the use of Animals in Ophthalmic and Vision research. VEGFLacZ and c57BL/6 mice of approximately equal weights between the ages of 6 and 10 weeks were used.
Experimental corneal NV
bFGF pellets consist of the slow-release polymer Hydron (polyhydroxyethylmethacrylate) containing a combination of 45 ng/pellet of sucralfate (Sigma-Aldrich, St. Louis, MO, uSA) with or without 80 ng/pellet of bFGF (r&d Systems, Minneapolis, Mn, uSA) and were made as previously described by Kenyon et al (19) . Briefly, a suspension of sterile saline containing the appropriate amount of recombinant bFGF and sucralfate was made and speed vacuumed for 5 minutes. ten μL of 12% Hydron in ethanol was added to the suspension, which was then deposited onto a sterilized 15 mm 2 piece of nylon mesh (LAB Pak, Sefar America, depew, nY, uSA) and embedded between the fibers. the resulting grid of 10 x 10 mm squares was allowed to dry on a sterile Petri dish for 60 minutes. the fibers of the mesh were separated under a microscope and among the approximately 100 pellets produced, 30 to 40 uniformly sized pellets of 0.4 x 0.4 x 0.2 mm 3 were selected for implantation. All procedures were performed under sterile conditions. the pellets can into mice immediately before bFGF pellet implantation in the cornea (n = 5 mice/group). Antibiotic ophthalmic ointment was applied after bFGF pellet implantation. Five additional mice with bFGF pellets served as controls. the extent of corneal nV was photographed and quantified on days 4 and 7 after bFGF implantation. Subsequent experiments were performed to confirm the corneal bioavailability of VEGF trap r1r2 and hFc in our model by goat anti-human Fc antibody (#G-102-c, r&d Systems).
rESuLtS
bFGF induces VEGF expression in mouse corneas
the extent of corneal nV was assayed using bFGF pellets of 80 ng implanted into mouse corneas. new vessel growth began at day 4 postintrastromal bFGF pellet implantation and progressed until day 21 (Fig. 1) . VEGF expression was noted in the epithelium and perivascularly at day 4 (Fig. 1G) .the level of VEGF peaked on day 7 (Fig. 1I ) in the epithelium and corneal stroma, and diminished gradually by days 10, 14, and 21 (Fig. 1) . Miquerol et al generated VEGF-LacZ mice by inserting a reporter gene into the 3' untranslated region of the endogenous VEGF gene so that VEGF and the LacZ reporter mrnA are produced from a bicistronic mrnA (21). using corneas from these VEGF-LacZ mice, the expression of VEGF and corneal vessels were visualized after injections of FItc-conjugated lectin into the tail vein. LacZ expression was noted in activated stromal cells on day 4 (Fig. 2E ) and increased on day 7 (Fig. 2F) after bFGF pellet implantation. bFGF pellet-implanted corneas were harvested and sectioned into a set of 3 mirror-image segments (Fig. 2, G and  H) . Lysates of these sections were analyzed by Western blot analysis using an anti-VEGF antibody. corneal segments with vascularization showed maximal VEGF expression at the area of the bFGF pellet. Blocking of bFGF-induced corneal nV via VEGF trap r1r2 Mice were given a 12.5 mg/kg intraperitoneal injection of VEGF trap r1r2 before corneal implantation of an 80 ng bFGF pellet. Mouse corneas implanted with a bFGF pellet with or without 12.5 mg/kg intraperitoneal injection of hFcprotein were used as controls. the distance of the pellet to the limbus was measured by 3 observers for each corneal image as described in Materials and Methods. there was IgG antibody (both from Jackson Immunoresearch Laboratories, West Grove, PA, uSA). Sections were viewed with a Leica tcS SP2 cLSM confocal laser scanning microscope (Leica, Heidelberg, Germany). VEGF-LacZ mice were implanted with either a bFGF pellet or a blank pellet. the mice received 8 μg/g tail vein injections of an endothelial-specific, fluorescein-conjugated lectin (lycopersicin esculentum) on days 1, 4, and 7 postpellet implantation. Mice were then killed and whole eyes were harvested and fixed in 10% neutral, buffered formalin for 24 h. the corneas were dissected and placed in blocking solution (1% BSA) for 4 hours. the corneas were then incubated with a 1:200 dilution of biotin-conjugated IgG fraction of anti-ß-galactosidase antibody (rockland Immunochemicals research Inc., Gilbertsville, PA, uSA) overnight, rinsed in PBS, and incubated with a 1:1000 dilution of rhodamine-conjugated streptavidin (rockland) for 2 h. the specimens were rinsed in PBS and mounted on glass slides with Vectashield mounting medium for fluorescence imaging (Vector Laboratories, Burlingame, cA, uSA). Fluorescence in the perfused vessels and LacZ expression was captured using a Leica tcS SP2 cLSM confocal laser scanning microscope.
Western blot analysis for VEGF expression
Wild-type mouse corneas were collected on day 7 after bFGF pellet implantation. corneas were sectioned, homogenized, lysed with lysis buffer, and run on 4% to 20% SdS polyacrylamide gels (novex, San diego, cA, uSA). Proteins were electrotransferred onto nylon membranes (Immobilon P, Millipore, Bedford, MA, uSA), blotted with 3% BSA for 30 minutes, and incubated for 1 hour with anti-VEGF antibody (r&d Systems, #AF-493-nA; 1:1000 dilution). Subsequently, horseradish peroxidase donkey antigoat IgG (1:20,000, GE Life Science, Piscataway, nJ, uSA) was used as secondary antibody. Human VEGF was used as a standard control (1:100). After washing with tris-buffered saline tween-20 (tBSt) for 15 min, immunoblots were developed with an enhanced chemiluminescence (EcL) reagent (Perkin-Elmer, Waltham, MA, uSA).
Intraperitoneal injection of VEGF Trap R1R2 into mouse after corneal bFGF pellet implantation
VEGF trap r1r2 12.5 mg/kg or human Fc domain protein (hFc) (12.5 mg/kg; control) were intraperitoneally injected surface. the pathologic condition of corneal nV may result from the production of angiogenic factors by local epithelial cells, keratocytes, and infiltrating leukocytes (22). during corneal nV, these angiogenic factors may directly or indirectly stimulate vascular endothelial cells to proliferate, migrate, and form new blood vessels. Implantation of bFGF pellets in mouse corneas stimulates corneal vessel formation originating from the limbal area (19). In this study, we investigated the role of VEGF in bFGF-induced corneal nV. Our results suggest that bFGF stimulates VEGF production in corneal keratocytes. In the corneal nV assay, vessels were visualized on day 4, peaked on day 7, and extended to day 21 following bFGF pellet implantation, with a concomitant increase in VEGF expression in the stroma. A similar experiment reported that corneas implanted with sham pellets do not induce corneal nV (23). cursiefen et al have demonstrated that VEGF trap r1r2 , a soluble VEGF antagonist molecule, binds VEGF-A and no significant difference in the distance of pellets to limbus among the 3 groups (control = 1.01 mm±0.17 mm; hFc = 1.21 mm±0.22 mm; VEGF trap = 1.10 mm±0.20 mm; p=0.30). Following bFGF pellet implantation, the area of corneal nV in untreated controls was 1.05±0.12 mm 2 and 1.53±0.27 mm 2 at days 4 and 7, respectively. this was significantly greater than that of mice treated with VEGF trap r1r2 (Fig. 3, c and F ; 0.24±0.11 mm 2 and 0.35±0.16 mm 2 at days 4 and 7, respectively; p<0.05). corneas displayed bFGF-induced nV on day 7 in the hFc protein intraperitoneal-treated group (Fig. 3, B and d; 1.21±0.07 mm 2 and 2.25±0.30 mm 2 at days 4 and 7, respectively). the results are summarized in Figure 3G . dIScuSSIOn corneal nV usually is associated with inflammatory, infectious, degenerative, and traumatic disorders of the ocular day 1 (D), day 4 (F), day 7 (H), day 10 (J), day 14 (L),  and day 21 (N) . A blank pellet was implanted as the control (A). bFGF pellet localization was shown in the transversal eye (B) and the intrastromal section (C). H J activity and can be detected at the single-cell level. LacZ expression was enhanced in the corneal keratocytes after bFGF pellet implantation in these VEGF-LacZ transgenic mice. the difference of the detection of VEGF expression after bFGF-pellet implantation in Wt (c57BL/6) and VEGFLacZ (129/sv) mice at day 1 may be due to different genetic backgrounds or the different antibodies used in immunostaining. Our findings are consistent with other reports showing that bFGF-induced corneal nV may be mediated via VEGF. the PlGF but not VEGF-c and VEGF-d in vitro, and in mice, an intraperitoneal injection of VEGF trap r1r2 blocked suture-induced corneal vessel formation (24). We used similar conditions in our experiments, and show that VEGF trap r1r2 blocked bFGF-pellet-induced corneal nV, much like the VEGF trap r1r2 -mediated block of suture-induced corneal nV (24). We also used VEGF-LacZ transgenic mice to detect VEGF expression (21). this allele allows independent translation of VEGF and LacZ from the same mrnA and reporter In this report, the experiments are consistent with the hypothesis that bFGF stimulates corneal keratocytes to produce VEGF. these data suggest that experimental corneal nV using bFGF pellets in mouse corneas can be blocked by systemic administration of VEGF trap r1r2 . In addition to its potential therapeutic applications for ocular angiogenesis, VEGF trap r1r2 mechanisms may lead to a better understanding of corneal nV and possibly its prevention.
Sections of corneas were stained with anti-VEGF and anti-CD-31 antibodies on days 1 (E), 4 (G), 7 (I), 10 (K), 14 (M), and 21 (O). VEGF expression was noted in the corneal epithelium at day 1 (E). VEGF expression in the corneal keratocytes peaked on day 7 (I) and its expres-
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The authors thank Dr. A. Nagy for providing VEGF-LacZ mice for this study. (18). the bFGF-induced corneal nV can be partially blocked by using a neutralizing anti-VEGF antibody. chang et al and cursiefen have both demonstrated that VEGF also plays a role in bFGF-induced corneal lymphangiogenesis and angiogenesis (22, 25) . corneal suture or bFGF-pellet implantation recruits neutrophils and macrophages to the wounded cornea and produce VEGF, VEGF-c, and VEGF-d, which further induces corneal nV. However, information regarding the production of VEGF by resident cells (keratocytes) in corneal angiogenesis is limited. Fig. 3 
